GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Debt-to-Asset

Apollomics (Apollomics) Debt-to-Asset : 0.08 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Debt-to-Asset?

Apollomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.39 Mil. Apollomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.27 Mil. Apollomics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $55.39 Mil. Apollomics's debt to asset for the quarter that ended in Dec. 2023 was 0.08.

Apollomics Debt-to-Asset Historical Data

The historical data trend for Apollomics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Debt-to-Asset Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
0.01 0.01 0.01 0.08

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial 0.01 0.01 0.01 0.01 0.08

Competitive Comparison of Apollomics's Debt-to-Asset

For the Biotechnology subindustry, Apollomics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Apollomics's Debt-to-Asset falls into.


Apollomics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Apollomics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.394 + 0.267) / 55.387
=0.08

Apollomics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.394 + 0.267) / 55.387
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics  (NAS:APLMW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Apollomics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Apollomics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics (Apollomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Debt-to-Asset
Comparable Companies
ATHA STTK ACXP CARA TLSA ORMP IMMX CCCC GTHX GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
APLM:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.